Patents Challenged by Apotex's Ruxolitinib ANDA
Apotex filed an Abbreviated New Drug Application (ANDA) for a generic version of ruxolitinib (Jakafi), targeting Incyte Corporation and Novartis's patents. The filing included Paragraph IV certifications, triggering Hatch-Waxman litigation. Apotex challenged 13 Orange Book-listed patents covering Jakafi's topical cream formulation (for atopic dermatitis and vitiligo) and related methods.[1][2]
Key Patents in the Lawsuit
The main patents asserted against Apotex's ANDA (21 U.S.C. § 355(j)(2)(A)(vii)(IV)) are:
| Patent No. | Title/Description | Expiration (with extensions) |
|------------|-------------------|-----------------------------|
| US 9,815,806 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 10,053,425 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 10,646,420 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 10,675,249 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,083,664 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,154,474 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,298,329 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,382,857 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,446,279 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,491,096 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,511,958 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,590,996 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
| US 11,839,529 | Certain topical formulations of ruxolitinib [2] | Dec 15, 2032 |
These cover cream compositions, manufacturing processes, and therapeutic uses. Incyte/Novartis sued Apotex in the District of Delaware (Case 1:24-cv-00749, filed June 2024).[1]
Why These Patents Matter
Apotex's Paragraph IV challenge argues non-infringement, invalidity, or unenforceability. Success could allow generic entry by 2025 (post-30-month stay), ahead of 2032 expiry. Opdivo (ruxolitinib phosphate) oral patents expire earlier (e.g., US 8,158,616 in 2027), but Apotex targets the lucrative topical market ($500M+ annual sales).[3]DrugPatentWatch.com
Status of Litigation and Other Challengers
The case is ongoing; no rulings yet. Other generics (e.g., Dr. Reddy's, Lupin) have filed similar ANDAs challenging overlapping patents, consolidating competitive pressure.[1] Oral Jakafi generics face separate suits, with some patents delisted post-PTAB invalidations.DrugPatentWatch.com
When Could Generics Launch?
If Apotex wins, launch possible after FDA tentative approval and stay expiration (Dec 2026). Patent thickets delay broader entry to 2032+.DrugPatentWatch.com (related topical branding).
Sources:
[1] PACER - Incyte v. Apotex (Del. 2024)
[2] FDA Orange Book - Jakafi/Opzelura Patents
[3] DrugPatentWatch.com - Ruxolitinib Patent Landscape